Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06424444 · ClinicalTrials.gov registry record · Phase 3
A Clinical Trial to Assess the Safety and Efficacy of Subjects With Dry Eye Disease
A Phase 3 study, sponsored by Aldeyra Therapeutics.
- Completed
- Registry status
- Phase 3
- Development phase
- 421
- Enrollment target
NCT06424444 is a Phase 3 study that has completed, run by Aldeyra Therapeutics. The registered enrollment target is 421 participants.
The verdict
NCT06424444, a Phase 3 study, has completed, sponsored by Aldeyra Therapeutics.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 421 participants
- Enrollment target
Study Summary
A Multicenter, Phase 3, Randomized, Double-Masked, Parallel-Group, Vehicle-Controlled, Environment Exposure Clinical Trial to Assess the Efficacy and Safety of 0.25% Reproxalap
Interventions
- DRUG Vehicle ophthalmic solution
- DRUG Reproxalap ophthalmic solution (0.25%)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 421 participants |
| Start Date | 2024-04-29 |
| Est. Completion | 2024-11-03 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06424444
The ClinicalTrials.gov registry entry for NCT06424444 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 421 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Aldeyra Therapeutics, which has 26 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Vehicle ophthalmic solution is the first listed.
NCT06424444 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT06424444 about?
NCT06424444 is a clinical study titled "A Clinical Trial to Assess the Safety and Efficacy of Subjects With Dry Eye Disease". A Multicenter, Phase 3, Randomized, Double-Masked, Parallel-Group, Vehicle-Controlled, Environment Exposure Clinical Trial to Assess the Efficacy and Safety of 0.25% Reproxalap
What is the current status of trial NCT06424444?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 421 participants. The study started on 2024-04-29. Estimated completion is 2024-11-03.
What interventions are being tested in trial NCT06424444?
The interventions under investigation include: Vehicle ophthalmic solution (DRUG), Reproxalap ophthalmic solution (0.25%) (DRUG).
Who is sponsoring clinical trial NCT06424444?
This trial is sponsored by Aldeyra Therapeutics, which has 26 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.